An unexpected relationship between two of the most frequent cancer-causing factors might lead to more effective drugs. According to a recent study from the University of Wisconsin-Madison, two of the most common genetic changes that result in cancerous cells, which were previously believed to be di
The study discovered connections between the PI3K/Akt and p53 pathways that provide potential targets for novel cancer treatments.
Cells manufacture a protein called p53, which functions within the cell nucleus to react to stress, but mutations in the gene that makes p53 are the most common genetic abnormalities in cancer. Runaway cell proliferation in cancer is also often linked to mutations that activate a cell’s surface-located pathway called PI3K/Akt.
A team led by UW–Madison cancer researchers Richard A. Anderson and Vincent Cryns has discovered a direct link between the p53 and PI3K/Akt pathways. The findings, recently published in the journalidentified links in the pathways that make promising targets for new cancer treatments. Instead of entering apoptosis — the proactive process of cell suicide which removes damaged cells — the cancer cells repaired their chemotherapy-damaged DNA and went on growing and dividing, promoting cancer growth.“Our finding that the PI3K/Akt pathway is anchored on p53 in the nucleus was entirely unexpected,” says Cryns, a physician-scientist and professor at UW School of Medicine and Public Health.“These results also have critical implications for cancer treatment,” Cryns says.
The team had previously shown that PIPKIa stabilizes the p53 protein, allowing it to be active. When PIPKIa was turned off, p53 levels inside the cell fell sharply. In the new study, the team showed that blocking PIPKIa by genetic approaches or a drug triggered cancer cell death by preventing p53 from activating Akt in the cell nucleus.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Generic Prostate-Cancer Drug Backed by Hospital Group Goes on SaleHospital-drugmaking venture Civica has begun selling a generic version of prostate-cancer drug Zytiga. It recommends pharmacies sell the drug, which can list for $3,000 a month, for no more than $171 a month
Baca lebih lajut »
A cancer survivor is fighting the DMV to keep her ‘FCANCER’ license plateKari Overington said she was “thrilled” when she got her “FCANCER” license plate and “devastated” when she learned state officials were taking it away.
Baca lebih lajut »
PolitiFact - No medical evidence that root canals cause cancerDespite its reemergence on social media, the notion that root canals cause cancer has been previously debunked and remains false.
Baca lebih lajut »
Utah cancer center study shows patients' need for mental health treatmentNew research out of the Huntsman Cancer Institute shows the need for more mental health treatment when it comes to patients, particularly those with Hodgkin Lymphoma diagnoses.
Baca lebih lajut »
Home screening test for oral or throat cancer has 90 per cent accuracyDiagnosing oral and throat cancers early is difficult because lesions need to be large enough for doctors to see. Now a new at-home saliva test could identify these cancers before they are visible
Baca lebih lajut »
Precision cancer targeting with antibody pairs - Nature BiotechnologyLogic-gated monoclonal antibodies have been designed to improve safety and efficacy NBTNV
Baca lebih lajut »